
by Antiverse
Antiverse combines generative AI with in-house antibody discovery to design biologics for GPCRs and other hard targets. It works with pharma partners.
Web appContact for pricing
Step 1: Contact Antiverse about your target.
Step 2: Agree a partnership scope.
Step 3: Antiverse designs candidates with its generative models.
Step 4: Candidates are tested in its wet lab.
Step 5: Review the prioritised clones.
GPCRs and other challenging targets such as ion channels.
Any biologic format with a heavy chain, including mAbs and VHH.
Prioritised clones maintain their natural conformation, enabling characterisation in 1 month.
Cardiff, UK, with offices in Boston and Prague.
ConsensusConsensus is an AI search engine for peer-reviewed research. It finds papers, analyzes them with citations, and shows how much the evidence agrees.